Cardiovascular

Medtronic Keeps DES Market Hot with New Indication

The Dublin-based company received approval for an expanded chronic total occlusion indication for its Resolute DES platform.

6 Emerging Cardiology Solutions in Late-Stage Research at Georgia Tech and Emory University

Biotronik Has a New DES Added to its Repertoire

The Lake Oswego, OR-based company has received a nod from FDA for the Orsiro stent which it said outperformed Abbott’s Xience stent in a clinical study.

Foldax Wins IDE for Surgical Aortic Heart Valve Trial

The Salt Lake City-based company said its Tria device is one of the first biopolymer heart valve platforms.

Is CRM a Better Alternative than Stress Echocardiograms?

Duke University Medical Center researchers looked at data from 9,000 patients who underwent Cardiac Magnetic Resonance.

Can This Wirelessly Charging Heart Pump Reshape the LVAD Market?

The Fully Implanted Ventricular Assist Device was developed using technologies from Jarvik Heart and Leviticus Cardio.

Will AI Play a Large Role for Edwards in 2019?

Edwards might be primarily known for its TAVR systems, but the company has been making some interesting forays into the artificial intelligence realm.

A New Way to Model the Heart Valve

University of Texas Engineers have developed a noninvasive way to simulate repairs to the heart's mitral valve allowing surgeons to provide patient-specific treatments.

New Imaging Tool Gives Greater View of Capillaries

The imaging process was developed by a team of researchers from Northwestern University and could help lead to the early diagnosis of disease.

Endologix’s CE Mark for Nellix is Suspended

The suspension follows the Irvine, CA-based company’s voluntary recall of the device earlier this month.

FDA Investigating Paclitaxel Coated Balloons and Eluting Stents

Prompted by a recent publication in the Journal of the American Heart Association that suggests a possible increased risk of death at two years and beyond in patients treated with vascular balloons coated with paclitaxel or stents that release paclitaxel, FDA said it is evaluating data and working directly with manufacturers to better understand this issue.